Aclaris Therapeutics, Inc. (LON:0H8T)
 2.495
 -0.040 (-1.58%)
  At close: Nov 3, 2025
Aclaris Therapeutics Revenue
Aclaris Therapeutics had revenue of $1.78M USD in the quarter ending June 30, 2025, a decrease of -35.76%. This brings the company's revenue in the last twelve months to $16.79M, down -47.56% year-over-year. In the year 2024, Aclaris Therapeutics had annual revenue of $18.72M, down -40.09%.
Revenue (ttm) 
 $16.79M
Revenue Growth 
 -47.56%
P/S Ratio 
 17.22
Revenue / Employee 
 $262.33K
Employees 
 64
Market Cap 
210.97M GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth | 
|---|---|---|---|
| Dec 31, 2024 | 18.72M | -12.53M | -40.09% | 
| Dec 31, 2023 | 31.25M | 1.50M | 5.03% | 
| Dec 31, 2022 | 29.75M | 22.99M | 340.05% | 
| Dec 31, 2021 | 6.76M | 279.00K | 4.30% | 
| Dec 31, 2020 | 6.48M | 2.26M | 53.35% | 
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue | 
|---|---|
| AstraZeneca | 41.24B | 
| GSK plc | 32.17B | 
| Haleon | 11.02B | 
| Smith & Nephew | 4.33B | 
| Hikma Pharmaceuticals | 2.35B | 
| ConvaTec Group | 1.72B | 
| Spire Healthcare Group | 1.55B | 
| Genus | 672.80M | 
Aclaris Therapeutics News
- 5 days ago - Aclaris Therapeutics to Participate in Three November Healthcare Conferences - GlobeNewsWire
 - 20 days ago - Aclaris Therapeutics, Inc. - Special Call - Seeking Alpha
 - 20 days ago - Aclaris Therapeutics, Inc. (ACRS) Special Call - Slideshow - Seeking Alpha
 - 4 weeks ago - Aclaris Therapeutics to Host In-Person and Webcast R&D Day, “Patient Focused Innovation: Addressing Gaps in Immuno-Inflammatory Markets”, in New York on October 14, 2025 - GlobeNewsWire
 - 7 weeks ago - Aclaris Therapeutics Announces Late-Breaking Abstract and Oral Presentation On ATI-2138 Phase 2a Results at the 2025 European Academy of Dermatology and Venereology (EADV) Congress - GlobeNewsWire
 - 2 months ago - Aclaris Therapeutics to Participate in Two September Healthcare Conferences - GlobeNewsWire
 - 3 months ago - Aclaris Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
 - 3 months ago - Aclaris Therapeutics Stock Spikes In After‑Hours Session Following Major Announcement - Benzinga